company background image
FHTX

Foghorn Therapeutics NasdaqGM:FHTX Stock Report

Last Price

US$8.38

Market Cap

US$350.3m

7D

6.5%

1Y

-40.3%

Updated

27 Jan, 2023

Data

Company Financials +

Foghorn Therapeutics Inc.

NasdaqGM:FHTX Stock Report

Mkt Cap: US$350.3m

FHTX Stock Overview

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system.

FHTX fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

New

Notes are coming soon

Foghorn Therapeutics Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Foghorn Therapeutics
Historical stock prices
Current Share PriceUS$8.38
52 Week HighUS$18.12
52 Week LowUS$5.32
Beta1.88
1 Month Change49.11%
3 Month Change2.82%
1 Year Change-40.27%
3 Year Changen/a
5 Year Changen/a
Change since IPO-53.75%

Recent News & Updates

Foghorn Therapeutics: Selling For Less Than Cash Value

Oct 10

Recent updates

We're Hopeful That Foghorn Therapeutics (NASDAQ:FHTX) Will Use Its Cash Wisely

Apr 13
We're Hopeful That Foghorn Therapeutics (NASDAQ:FHTX) Will Use Its Cash Wisely

Are Insiders Buying Foghorn Therapeutics Inc. (NASDAQ:FHTX) Stock?

Feb 27
Are Insiders Buying Foghorn Therapeutics Inc. (NASDAQ:FHTX) Stock?

Shareholder Returns

FHTXUS BiotechsUS Market
7D6.5%0.7%2.3%
1Y-40.3%7.1%-9.7%

Return vs Industry: FHTX underperformed the US Biotechs industry which returned 10.5% over the past year.

Return vs Market: FHTX underperformed the US Market which returned -8.5% over the past year.

Price Volatility

Is FHTX's price volatile compared to industry and market?
FHTX volatility
FHTX Average Weekly Movement12.7%
Biotechs Industry Average Movement12.2%
Market Average Movement6.9%
10% most volatile stocks in US Market17.3%
10% least volatile stocks in US Market2.9%

Stable Share Price: FHTX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: FHTX's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2015119Adrian H. Gottschalkhttps://foghorntx.com

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma.

Foghorn Therapeutics Inc. Fundamentals Summary

How do Foghorn Therapeutics's earnings and revenue compare to its market cap?
FHTX fundamental statistics
Market CapUS$350.30m
Earnings (TTM)-US$109.14m
Revenue (TTM)US$15.76m

22.2x

P/S Ratio

-3.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
FHTX income statement (TTM)
RevenueUS$15.76m
Cost of RevenueUS$99.87m
Gross Profit-US$84.12m
Other ExpensesUS$25.02m
Earnings-US$109.14m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.61
Gross Margin-533.83%
Net Profit Margin-692.64%
Debt/Equity Ratio0%

How did FHTX perform over the long term?

See historical performance and comparison